This company has been marked as potentially delisted and may not be actively trading. Jupiter Neurosciences (JUNS) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesInsider TradesTrendsBuy This Stock JUNS vs. ENGN, EPRX, GNFT, TLSI, OGI, UTMD, NLTX, HITI, OMER, and PROKShould you be buying Jupiter Neurosciences stock or one of its competitors? The main competitors of Jupiter Neurosciences include enGene (ENGN), Eupraxia Pharmaceuticals (EPRX), GENFIT (GNFT), TriSalus Life Sciences (TLSI), Organigram Global (OGI), Utah Medical Products (UTMD), Neoleukin Therapeutics (NLTX), High Tide (HITI), Omeros (OMER), and ProKidney (PROK). These companies are all part of the "medical" sector. Jupiter Neurosciences vs. Its Competitors enGene Eupraxia Pharmaceuticals GENFIT TriSalus Life Sciences Organigram Global Utah Medical Products Neoleukin Therapeutics High Tide Omeros ProKidney enGene (NASDAQ:ENGN) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Which has higher earnings and valuation, ENGN or JUNS? Jupiter Neurosciences has higher revenue and earnings than enGene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$55.14M-$1.65-2.01Jupiter Neurosciences$230K329.56-$2.44MN/AN/A Is ENGN or JUNS more profitable? Jupiter Neurosciences' return on equity of 0.00% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -32.60% -28.26% Jupiter Neurosciences N/A N/A N/A Do institutionals and insiders believe in ENGN or JUNS? 64.2% of enGene shares are held by institutional investors. 10.4% of enGene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer ENGN or JUNS? enGene currently has a consensus price target of $23.29, indicating a potential upside of 603.50%. Given enGene's higher probable upside, analysts plainly believe enGene is more favorable than Jupiter Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Jupiter Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Does the media refer more to ENGN or JUNS? In the previous week, enGene had 26 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 31 mentions for enGene and 5 mentions for Jupiter Neurosciences. Jupiter Neurosciences' average media sentiment score of 0.94 beat enGene's score of -0.22 indicating that Jupiter Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 2 Very Positive mention(s) 5 Positive mention(s) 12 Neutral mention(s) 7 Negative mention(s) 4 Very Negative mention(s) Neutral Jupiter Neurosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryJupiter Neurosciences beats enGene on 6 of the 11 factors compared between the two stocks. Get Jupiter Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for JUNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JUNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JUNS vs. The Competition Export to ExcelMetricJupiter NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.80M$415.98M$5.61B$9.11BDividend YieldN/A2.45%5.24%4.02%P/E RatioN/A7.2127.9620.25Price / Sales329.563.36430.8999.65Price / CashN/A8.4137.4658.16Price / Book17.620.898.045.49Net Income-$2.44M$10.55M$3.18B$250.27M Jupiter Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JUNSJupiter NeurosciencesN/A$2.29+19.9%N/AN/A$75.80M$230K0.005News CoverageHigh Trading VolumeENGNenGene2.6726 of 5 stars$3.81+0.3%$23.29+511.2%-63.2%$194.20MN/A-2.3131Trending NewsEPRXEupraxia Pharmaceuticals2.3844 of 5 stars$5.54+2.8%$11.00+98.6%+107.6%$193.81MN/A-7.2929Positive NewsGap UpGNFTGENFIT2.3145 of 5 stars$3.69-4.8%$13.00+252.7%-17.1%$193.49M$76.77M0.00120News CoverageTLSITriSalus Life Sciences3.0152 of 5 stars$4.96-2.2%$10.75+116.7%-8.8%$191.84M$32.14M-4.43106OGIOrganigram Global0.953 of 5 stars$1.39-2.8%N/A-14.7%$191.53M$117.47M13.90860UTMDUtah Medical Products1.9818 of 5 stars$57.19-2.1%N/A-18.6%$189.82M$40.90M15.13180Positive NewsNLTXNeoleukin TherapeuticsN/A$20.09+1.7%N/A-49.1%$188.81MN/A-6.4690HITIHigh Tide2.4396 of 5 stars$2.31-0.4%$4.75+105.6%+14.6%$188.39M$381.22M-28.881,550Positive NewsOMEROmeros3.5746 of 5 stars$3.08-3.8%$18.00+484.4%-14.1%$187.50MN/A-1.16210News CoverageGap DownPROKProKidney2.6517 of 5 stars$0.61-4.8%$3.50+477.1%+89.2%$186.51M$306K-1.013News CoverageAnalyst ForecastInsider TradeGap Down Related Companies and Tools Related Companies ENGN Competitors EPRX Competitors GNFT Competitors TLSI Competitors OGI Competitors UTMD Competitors NLTX Competitors HITI Competitors OMER Competitors PROK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JUNS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s whole-government AI plans leakedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JUNS Stock Alerts